Company News
Mirum to Present Phase 3 LIVMARLI Results
Mirum Pharmaceuticals will host an investor call Monday at 8:30 a.m. ET to present Phase 3 EXPAND study topline results for LIVMARLI.
The Phase 3 study evaluates LIVMARLI (maralixibat) for cholestatic
